CARMIEL, Israel, Sept. 6,
2023 /PRNewswire/ -- Protalix
BioTherapeutics, Inc. (NYSE American: PLX), a
biopharmaceutical company focused on the development, production
and commercialization of recombinant therapeutic proteins produced
by its proprietary ProCellEx® plant cell–based protein
expression system, today announced that Dror Bashan, the Company's President and Chief
Executive Officer, will present on Wednesday, September 13,
2023 at 3:00 p.m. Eastern Daylight Time (EDT) at the
H.C. Wainwright 25th Annual Global Investment Conference. The
conference is being held on September 11-13, 2023 at the Lotte
New York Palace Hotel, New York
City, NY.
Mr. Bashan will provide a live corporate overview at the
conference, and will participate in one-on-one meetings with
investors who are registered to attend the conference.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell-based
expression system, ProCellEx. It is the first company to gain
U.S. Food and Drug Administration (FDA) approval of a protein
produced through a plant cell-based in suspension expression
system. This unique expression system represents a new method for
developing recombinant proteins in an industrial-scale manner.
Protalix has licensed to Pfizer Inc. the worldwide development and
commercialization rights to taliglucerase alfa for the treatment of
Gaucher disease, Protalix's first product manufactured through
ProCellEx, excluding in Brazil,
where Protalix retains full rights. Protalix's second product,
Elfabrio®, was approved by both the FDA and the European
Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the
global development and commercialization of Elfabrio.
Protalix's development pipeline consists of proprietary versions
of recombinant therapeutic proteins that target established
pharmaceutical markets, including the following product candidates:
PRX-115, a plant cell-expressed recombinant PEGylated uricase for
the treatment of severe gout; PRX-119, a plant cell-expressed long
action DNase I for the treatment of NETs-related diseases; and
others.
Investor Contact
Chuck Padala, Managing
Director
LifeSci Advisors
+1-646-627-8390
Logo -
https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301919041.html
SOURCE Protalix BioTherapeutics, Inc.